Evidence map›Paper›PMID 30009933›Full record

ReviewPharmacological research2019

Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder.

Valentina R Garbarino, T Lee Gilman, Lynette C Daws, Georgianna G Gould

Open access · greenAbstract readReview
In one paragraph

Review in Pharmacological research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Metabolomic changes in children with autism.World journal of clinical pediatrics · 2024
    Article
  15. Sex differences in offspring risk and resilience following 11β-hydroxylase antagonism in a rodent model of maternal immune activation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Valentina R GarbarinoDepartment of Cellular and Integrative Physiology, United States; The Sam and Ann Barshop Institute for Longevity and Aging Studies, United States. Electronic address: garbarino@livemail.uthscsa.edu.
T Lee GilmanDepartment of Cellular and Integrative Physiology, United States; Addiction Research, Treatment & Training Center of Excellence, United States. Electronic address: gilmant@uthscsa.edu.
Lynette C DawsDepartment of Cellular and Integrative Physiology, United States; Addiction Research, Treatment & Training Center of Excellence, United States; Department of Pharmacology, United States. Electronic address: daws@uthscsa.edu.
Georgianna G GouldDepartment of Cellular and Integrative Physiology, United States; Center for Biomedical Neuroscience, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: gouldg@uthscsa.edu.
Connecticut Department of Mental Health and Addiction Services · USInstitute on Aging · USLaboratoire d’immunologie intégrative du cancer · FRThe University of Texas Health Science Center at San Antonio · US

Funding

TRAINING GRANT ON THE BIOLOGY OF AGINGT32AG021890 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Erzsebet Kokovay, JAMES FLOYD NELSON · 2003 to 2026
$11.4M
Role of the serotonin transporter and organic cation transporter 3 in serotonergic modulation of emotion-regulating circuitryR01MH093320 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAWS, LYNETTE C, TONEY, GLENN M · 2012 to 2023
$6.3M
Training in Drug Abuse Research: Behavior and NeurobiologyT32DA031115 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHARLES P FRANCE · 2011 to 2026
$5.2M
Age-related differences in serotonin clearance: novel targets for antidepressantsR01MH106978 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DAWS, LYNETTE C · 2015 to 2019
$2.5M
Impact of Gestational Serotonin Availability on Brain Function & Social BehaviorR21HD081261 · NICHD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GOULD, GEORGIANNA G. · 2015 to 2016
$416k
NIA NIH HHS T32 AG021890NICHD NIH HHS R21 HD081261NIDA NIH HHS T32 DA031115NIMH NIH HHS R01 MH093320NIMH NIH HHS R01 MH106978
6 · The paper itself

Abstract

A variety of human and animal studies support the hypothesis that serotonin (5-hydroxytryptamine or 5-HT) system dysfunction is a contributing factor to the development of autism in some patients. However, many questions remain about how developmental manipulation of various components that influence 5-HT signaling (5-HT synthesis, transport, metabolism) persistently impair social behaviors. This review will summarize key aspects of central 5-HT function important for normal brain development, and review evidence implicating perinatal disruptions in 5-HT signaling in the pathophysiology of autism spectrum disorder. We discuss the importance, and relative dearth, of studies that explore the possible correlation to autism in the interactions between important intrinsic and extrinsic factors that may disrupt 5-HT homeostasis during development. In particular, we focus on exposure to 5-HT transport altering mechanisms such as selective serotonin-reuptake inhibitors or genetic polymorphisms in primary or auxiliary transporters of 5-HT, and how they relate to neurological stores of serotonin and its precursors. A deeper understanding of the many mechanisms by which 5-HT signaling can be disrupted, alone and in concert, may contribute to an improved understanding of the etiologies and heterogeneous nature of this disorder. We postulate that extreme bidirectional perturbations of these factors during development likely compound or synergize to facilitate enduring neurochemical changes resulting in insufficient or excessive 5-HT signaling, that could underlie the persistent behavioral characteristics of autism spectrum disorder.

Indexed as

AnimalsAutism Spectrum DisorderHumansSelective Serotonin Reuptake InhibitorsSerotoninSerotonin Plasma Membrane Transport ProteinsSelective Serotonin Reuptake InhibitorsSerotoninSerotonin Plasma Membrane Transport ProteinsAutism spectrum disorderNeurodevelopmentSelective serotonin reuptake inhibitorsSerotonin homeostasisSerotonin transporterTryptophan

Identifiers

PMID30009933
PMCPMC6345621
OpenAlexW2884638905

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.